Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management



The quick guide (for use in conjunction with full guideline www.nos.org.uk/professionals/publications)

TEST

- Patients with diseases with outcomes that may be improved with vitamin D treatment e.g. confirmed osteomalacia, osteoporosis
- Patients with symptoms that could be attributed to vitamin D deficiency e.g. suspected osteomalacia, chronic widespread pain
- · Before starting patients on a potent antiresorptive agent

Maintain vitamin D through safe sun exposure and diet

250H vitamin D (nmol/L)

30-50

If one or more of following applies:

- Fragility fracture/osteoporosis/ high fracture risk
- Drug treatment for bone disease
- Symptoms suggestive of vitamin D deficiency
- Increased risk of developing vitamin D deficiency e.g.
 - Reduced UV exposure
 - Raised PTH
 - Treatment with anticonvulsants or glucocorticoids
 - Malabsorption

Treat

<30

Treat

Rapid correction if:

- Symptoms of vitamin D deficiency
- About to start treatment with potent antiresorptive agent (zoledronate or denosumab)
- Approximately 300,000 IU vitamin D3 (or D2) by mouth in divided doses over 6-10 weeks
- Commence maintenance vitamin D 4 weeks after loading as per elective correction*

HOW TO TREAT VITAMIN D DEFICIENCY

*Elective correction in all other instances

- When co-prescribing vitamin
 D supplements with an oral
 antiresorptive agent,
 maintenance therapy may
 be started without the use of
 loading doses.
- 800-2000 IU vitamin D3 daily or intermittently at higher equivalent dose

CAUTION

- Check serum adjusted calcium 4 weeks after treating with loading doses of vitamin D. Vitamin D repletion may unmask primary hyperparathyroidism
- Routine repeat vitamin D testing is not required

TRE/

VI

-OLLOW